Concepedia

350MO Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – Second interim efficacy analysis of the randomized phase III DETECT V trial

W Janni, T.N. Fehm, V. Mueller, A.M.B. de Gregorio, T. Decker, AD Hartkopf, Marianne Just, J. Sagasser, M Schmidt, Pauline Wimberger,

Annals of Oncology · 2024 · 10 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacologyBreast OncologyChemotherapyMolecular OncologyBreast Cancer OncologyBreast Cancer PharmacotherapyHer2-positive Breast CancerMetastatic Breast CancerMetastatic Disease TreatmentTyrosine Kinase InhibitorsCyclin-dependent Kinase 6 InhibitorsHer2-positive Metastatic DiseaseMetastatic Her2-positive Breast Cancer